NCT01585233已完成2 期
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 13
- 主要终点
- Pharmacokinetics of ASKP1240: Area under the curve 0-336 (AUC336 )
研究概览
简要总结
The purpose of this study is to explore the safety and tolerability of multiple doses of ASKP1240 compared to placebo and determine Pharmacokinetics and Pharmacodynamics in subjects with moderate to severe psoriasis.
详细描述
Treatment with ASKP1240 or placebo will be over 4 weeks (Baseline/Day 1, Days 15 and Day 29) with 12 weeks of follow-up for a total of 16 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a clinical diagnosis of moderate to severe plaque psoriasis for 6 months or longer with at least 5% or greater Body Surface Area (BSA) affected with plaque psoriasis
- •Subject must be a candidate for phototherapy and/or systemic therapy
- •Subject must agree to avoid prolonged exposure to the sun and avoid the use of tanning booths or other ultraviolet light sources during the study
- •Female subject must be either:
- •post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
- •premenarchal prior to Screening, or
- •documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening), or
- •if of childbearing potential, must have a negative serum pregnancy test at Screening and if sexually active must be using highly effective contraception. All sexually active subjects will be required to use highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
- •Female subject must not be lactating and must not be breastfeeding at Screening or during the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
- •Female subject must not donate ova starting at Screening and throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
- •Male subject and their female spouse/partners who are sexually active must be using highly effective contraception1 consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
- •Male subject must not donate sperm starting at Screening and throughout the study period and for at least 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.
- •Highly effective contraception is defined as:
- •Established use of oral, injected or implanted hormonal methods of contraception.
- •Placement of an intrauterine device (IUD) or intrauterine system (IUS)
- •Barrier methods of contraception: Condom alone or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
- •Subject must be willing and able to comply with the study requirements, including prohibited concomitant medication restrictions.
- •Waivers to the inclusion criteria will NOT be allowed.
排除标准
- •Subject has non-plaque psoriasis (such as guttate, erythrodermic or pustular psoriasis)
- •Subject has received treatment with systemic, non-biologic psoriasis therapy or other systemic immunosuppressant including investigational use of an approved agent within the last 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug
- •Subject has ever been treated with efalizumab (Raptiva®)
- •Subject has a total B lymphocyte count by flow cytometric determination that is less than the lower limit of normal
- •Subject has a hemoglobin, that are below the lower limit
- •Subject has a total white count, total lymphocyte count, total neutrophil count or total platelet that are below the lower limit
- •Subject has any of the following lab values:
- •ALT ≥ 1.5 x upper limit of normal
- •AST ≥ 1.5 x upper limit of normal
- •Total bilirubin ≥ 1.5 x upper limit of normal
- •Subject has previously received ASKP1240 or has participated in a study involving ASKP1240
- •Subject has > 45 body mass index (BMI)
- •Subject with a positive Tubercle Bacillus (TB) test who has not previously received adequate antimicrobial therapy for TB or is currently on, or is planned to start TB antimicrobial therapy
- •Subject has abnormal chest x-ray indicative of acute or chronic lung disease
- •Subject has uncontrolled intercurrent illness, including, but not limited to ongoing or active infection, any clinically significant cardiac disease seizure disorder, or psychiatric illness/social situations that would limit compliance with study requirements
- •Subject has a history of any malignancy regardless of the location and the time of diagnosis in the last 5 years (including in-situ carcinoma of the cervix, but excluding successfully treated non-metastatic basal cell and squamous cell carcinoma)
- •Subject has received live or live attenuated virus vaccinations within the last 30 days prior to first dose of study drug
- •Subject has received treatment with another investigational drug within 30 days or 5 half-lives; whichever is longer, prior to the initiation of Screening
- •Subject has a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
- •Subject has a history of a positive test for human immunodeficiency virus (HIV) infection
- •Subject has received treatment with systemic, biologic psoriasis therapy or other systemic immunosuppressant including investigational use of an approved agent within the last 56 days or 5 half-lives whichever is longer, prior to the first dose of study drug
- •Waivers to the exclusion criteria will NOT be allowed.
研究组 & 干预措施
Cohort 1
Experimental
ASKP1240 lowest dose
干预措施: ASKP1240 (Drug)
Cohort 2
Experimental
ASKP1240 low dose
干预措施: ASKP1240 (Drug)
Cohort 3
Experimental
ASKP1240 high dose
干预措施: ASKP1240 (Drug)
Cohort 4
Experimental
ASKP1240 highest dose
干预措施: ASKP1240 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Pharmacokinetics of ASKP1240: Area under the curve 0-336 (AUC336 )
时间窗: Day 1 to Day 113 (12 visits)
Pharmacokinetics of ASKP1240: Maximum Concentration (Cmax)
时间窗: Day 1 to Day 113 (12 visits)
Pharmacodynamic variable: CD40 receptor occupancy on peripheral blood B cells
时间窗: Day 1 to Day 113 (12 visits)
Characterize safety profile of ASKP1240 through adverse event reporting, vital signs, clinical laboratory evaluations, physical examinations and 12-lead electrocardiograms (ECGs)
时间窗: 113 Days
次要结局
- Cytokine Concentration(Day 1 to Day 113 (9 visits))
- Anti-ASKP1240 antibodies(Day 1 to Day 113 (8 visits ))
- Mean change from baseline to 8 weeks in Psoriasis Area Severity Index (PASI) score(Baseline and 8 weeks)
- Mean change from baseline to 8 weeks in Physicians Static Global Assessment (PSGA) score(Baseline and 8 weeks)
- Proportion of Subjects Achieving Treatment Success(8 weeks)
- Mean change from baseline to 8 weeks in % Body Surface Area (BSA)(Baseline and 8 weeks)
- Lymphocyte subset quantitation(Day 1 to Day 113 (9 visits))
研究者
研究点 (13)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015KHealthy SubjectsPharmacokinetics of ASP015KPharmacodynamicsNCT01364974Astellas Pharma Inc48
已完成
1 期
Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy SubjectsPharmacokinetics of ASKP1240Healthy VolunteersNCT01565681Astellas Pharma Global Development, Inc.109
已完成
2 期
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity StatinsHypercholesteremiaNCT02634151NeuroBo Pharmaceuticals Inc.105
已完成
1 期
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy ParticipantsAPOL1-mediated Kidney DiseaseNCT05324410Vertex Pharmaceuticals Incorporated88
已完成
2 期
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusLupus Erythematosus, SystemicLupusNCT00657189MedImmune LLC87